Pfizer Submits EUA for COVID-19 Vaccine Booster for All Adults
Previously, the FDA had issued an EUA for those over the age of 65 and those at high risk for severe COVID-19 or exposure to the virus.
Pfizer and BioNTech have requested the FDA amend its emergency use authorization (EUA) for a booster dose of their COVID-19 vaccine to include all people 18 years of age and older. This request is based on results from a phase 3 trial with more than 10,000 participants, which showed a relative vaccine efficacy of 95.6% when compared with those who did not receive a booster. The adverse event profile was consistent with other safety data and no new safety concerns were identified.
In September, the FDA issued an EUA for a booster dose of the Pfizer-BioNTech vaccine for people 65 years of age and older, as well as for those 18 through 64 years of age at high risk of severe COVID-19 or with occupational exposure. And in October, the FDA issued an EUA for the vaccine for children five years and up at a dose that is one-third that of the dose for adults.
The companies have shared the data from the phase 3 booster trial with the European Medicines Agency and other regulatory authorities. A booster dose of the vaccine is approved in the European Union and authorized/approved in other countries for individuals 18 years of age and older based on previously submitted safety, tolerability and immunogenicity data.
Related: FDA Issues EUA for Pfizer COVID-19 Vaccine for Children
This COVID-19 vaccine, now called Comirnaty, has contributed $13 billion in direct sales and alliance revenue for Pfizer, according to the company’s third-quarter results.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
